DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE

Ceramedix正在开发CX-01，这是一种很有前途的放射医学对策(MCM)，可以解决导致随后GI器官衰竭和死亡的辐射诱导的微血管(内皮)损伤。CX-01抑制辐射损伤的启动事件和微血管内皮细胞的凋亡。目前，还没有FDA批准的胃肠道急性辐射综合征(GI-ARS)的治疗方法。对不断升级的辐射暴露的生物反应的复杂性导致了动物研究平台的不断发展，以可靠地模拟电离辐射(IR)诱导的不同阶段的损伤，并将其战术应用于测试新型MCM。

Ceramedix is developing CX-01, a promising radiation medical countermeasure (MCM), that addresses radiation-induced microvascular (endothelial) injury that leads to subsequent GI organ failure and death. CX-01 inhibits the initiating event of radiation injury and microvascular endothelial apoptosis. Currently, there are no FDA-approved treatments for gastrointestinal acute radiation syndrome (GI-ARS) The complexity of the biological responses to escalating radiation exposures has led to continued development of animal research platforms for reliably modeling different stages of ionizing radiation (IR) induced injury with tactical application to testing novel MCMs.